terug| terug |
5 september 2002
Project "De Ouder Wordende Vrouw"
inleiding - medewerkers - projecten - websitePublicaties
2002 - 2001 - 2000 - 1999 - 1998 - 1997
2002
1. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women.
Post MS, Hendriks D, Mooren MJ van der, Baal WM van, Leurs JR, Emeis JJ, Kenemans P, Stehouwer CDA.
J Intern Med 2002;251:245-251.2. Oral, but not transdermal, low-dose 17ß-estradiol increases C-reactive protein in healthy postmenpausal women.
Post MS, Mooren MJ van der, Baal WM van, Mijatovic V, Schalkwijk CG, Stehouwer CDA, Kenemans P.
Thromb Haemost 2002; in press.3. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.
Smolders RGV, Vogelvang TE, Mijatovic V, Baal WM van, Neele SJM, Netelenbos JC, Kenemans P, Mooren MJ van der.
Maturitas 2002;41:105-114.4. 17ß-estradiol induces a rapid, endothelium-dependent, sex-specific, vasodilatation in spontaneous constricted rat arterioles.
Smolders RGV, Mooren MJ van der, Kenemans P, Stehouwer CDA, Sipkema P.
Am J Obstet Gynecol 2002;187:375-381.5. Effects of hormone replacement therapy on blood platelets.
Thijs A, Baal WM van, Mooren MJ van der, Kenemans P, Dräger AM, Huijgens PC, Stehouwer CDA
Eur J Clin Invest 2002;8:613-618.6. Neither lon-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.
Vogelvang TE, Mijatovic V, Kamp O, Netelenbos JC, Neele SJM, Pines A, Kenemans P, Mooren MJ van der.
Am J Obstet Gynecol 2002;186:729-736.
2001
1. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate.
Al-Azzawi F, Wahab M, Thompson J, Pornel B, Hirvonen E, Ylikorkala O, Mooren MJ van der, Dillon J, Magaril C.
Climacteric 2001;4:343-354.2. Climacteric symptoms in a representative Dutch population sample as measured with the Greene Climacteric Scale.
Barentsen R, Weijer PHM van de, Gend S van, Foekema H.
Maturitas 2001;38:123-128.3. Therapeutic value and long-term safety of pulsed estrogen therapy.
Dören M, Al-Azzawi FA, Donnez J, Mooren MJ van der, Villero J, Gompel A.
Maturitas 2001;38 Suppl 1:S23-30.4. Perspectives in hormone replacement therapy.
Kenemans P, Unnik GA van, Mijatovic V, Mooren MJ van der.
Maturitas 2001;38 Suppl 1:S41-48.5. Tissue specificity of sex hormones and so-called modulation of receptors and enzymes.
Kenemans P.
Maturitas 2001;37:145-146.6. Effects of 15 months of 17 beta-estradiol and dydrogesterone on systolic cardiac function according to quantitative and Doppler echocardiography in healthy postmenopausal women.
Kessel H, Kamp O, Kenemans P, Mijatovic V, Baal WM van, Visser CA, Mooren MJ van der.
Am J Obstet Gynecol 2001;184:910-916.7. Receptor selectivity, enzymes and tissue specificity.
Mijatovic V.
Maturitas 2001;37:147-149.8. Homocysteine in postmenopausal women and the importance of hormone replacement therapy.
Mijatovic V, Mooren MJ van der.
Clin Chem Lab Med 2001;39:764-767.9. Cardiovascular protection by postmenopausal hormone replacement therapy - the point of lower oestrogen dosages.
Mooren MJ van der.
Maturitas 2001;38;227-229.10. Critical comments: Hormone replacement therapy and cardiovascular disease - the AHA statement. Does it need revision already?
Mooren MJ van der.
Maturitas 2001;40:14-15.11. Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: A 2-year randomized, placebo-controlled study.
Post MS, Mooren MJ van der, Baal WM van, Neele SJM, Netelenbos C, Kenemans P.
Am J Obstet Gynecol 2001;185:557-562.
2000
1. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.
Baal WM van, Emeis JJ, Mooren MJ van der, Kessel H, Kenemans P, Stehouwer CDA.
Thromb Haemost 2000;83:29-34.
2. Cardiovascular disease risk and hormone replacement therapy (HRT): a review on randomised, controlled studies in postmenopausal women.
Baal WM van, Kooistra T, Stehouwer CD.
Curr Med Chem 2000;7:499-517.3. Gonadotropin-releasing hormone agonist plus 'add-back' for the treatment of endometriosis: A prospective, randomized, placebo-controlled, double-blind trial.
Franke HR, Weijer PHM van de, Pennings TMM, Mooren MJ van der.
Fertil Steril 2000,74:3:534-539
4. Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years.
Geelen JM van, Weijer PHM van de, Arnolds HT.
Int Urogynecol J Pelvic Floor Dysfunct 2000;11:9-14.
5. Endometrial safety and tolerability of AERODIOL for 1 year.
Gompel A, Bergeron C, Jondet M, Dhont M, Mooren MJ van der, Toth KS, Panay N, Holst T von.
Maturitas 2000:36:209-215.6. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.
Mattsson LA, Christiansen C, Colau JC, Kenemans P, Bergeron C, Chevallier O, Holst T von, Gangar K.
Am J Obstet Gynecol 2000;182:545-552.7. What to use, what to choose for the menopausal woman with high Lp(a).
Mijatovic V.
Maturitas 2000;30:55-57.8. Critical comments on the "Postmenopausal hormone therapy and coronary heart disease - clinical implications of recent randomized trial results", by Leon Speroff.
Mijatovic V.
Maturitas 2000;35:104-105.9. Menopause, oestrogens, SERMs and cardiovascular health in women.
Mijatovic V, Mooren MJ van der.
Eur J Obstet Gynecol Reprod Biol 2000;93:5-7.10. What to use, what to choose for the menopausal woman with hyperhomocysteinaemia.
Mooren MJ van der, Smolders RGV.
Maturitas 2000;30:57-59.
11. Critical comments on the "Postmenopausal hormone therapy and coronary heart disease - clinical implications of recent randomized trial results", by Leon Speroff.
Mooren MJ van der.
Maturitas 2000;35:101-103.12. Ultrasound assessment of the endometrium in healthy, asymptomatic early postmenopausal women: saline infusion sonohysterography versus transvaginal ultrasound.
Neele SJM, Baal WM van, Mooren MJ van der, Kessel H, Kenemans P, Netelenbos JC.
Ultrasound Obstet Gynecol 2000;16:254-259.13. Comparison of morphometric assessment of prevalent vertebral deformities in women using different reference data.
Szulc P, Munoz F, Sornay-Rendu E, Paris E, Souhami E, Zanchetti J, Bagur A, Mooren MJ van der, Young S, Delmas PD.
Bone 2000;27:841-806.14. New emerging risk factors for cardiovascular disease.
Smolders RGV, Mooren MJ van der.
J Brit Menopause Soc 2000;6:27-33.
15. Effects of estrogens and hormone replacement therapy on breast cancer risk and efficacy of breast cancer therapies.
Verheul HA, Coelingh-Bennink HJ, Kenemans P, Atsma WJ, Burger CW, Eden JA, Hammar M, Marsden J, Purdie DW.
Maturitas 2000;36:1-17.
1999
1. Hormone replacement therapy: beneficial as well as adverse effects on atherothrombotic risk?
Baal WM van.
Dissertation, 1999, Vrije Universiteit Amsterdam2. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women.
Baal WM van, Kenemans P, Mooren MJ van der, Kessel H, Emeis JJ, Stehouwer CDA.
Thromb Haemost 1999;81:925-928.3. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women.
Baal WM van, Kenemans P, Emeis JJ, Schalkwijk CG, Mijatovic V, Mooren MJ van der, Vischer UM, Stehouwer CDA.
Fertil Steril 1999;71:663-670.4. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules.
Baal WM van, Emeis JJ, Kenemans P, Kessel H, Peters-Muller ERA, Schalkwijk CG, Mooren MJ van der, Stehouwer CDA.
Eur J Clin Invest 1999;29:913-921.5. Sequentially combined hormone replacement reduces impedance to flow within the uterine and central retinal artery in healthy postmenopausal women.
Baal WM van, Kenemans P, Stehouwer CDA, Peters-Muller ERA, Vugt JMG van, Mooren MJ van der.
Am J Obstet Gynecol 1999;181:1365-1373.6. Hormone replacement therapy and plasma homocysteine levels.
Baal WM van, Smolders RGV, Mooren MJ van der, Teerlink T, Kenemans P.
Obstet Gynecol 1999;94:485-491.7. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.
Baal WM van, Emeis JJ, Mooren MJ van der, Kessel H, Kenemans P, Stehouwer CDA.
Thromb Haemost 2000;83:29-34.8. Hormone replacement therapy in women treated for gynecological malignancy.
Burger CW, Leeuwen FE van, Scheele F, Kenemans P.
Maturitas 1999;32:69-769. Micturation complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study.
Kok ALM, Burger CW, Weijer PHM van de, Voetberg GA, Peters-Muller ERA, Kenemans P.
Maturitas 1999;31:143-149.10. Postmenopausal hormone replacement and cardiovascular risk markers lipoprotein(a) and homocysteine.
Mijatovic V.
Dissertation, 1999, Vrije Universiteit Amsterdam11. Raloxifene lowers serum lipoprotein (a) in healthy postmenopausal women. A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
Mijatovic V, Mooren MJ van der, Netelenbos JC, Valk-de Roo GW de, Kenemans P.
Menopause 1999;6:134-137.12. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Review.
Mijatovic V, Mooren MJ van der, Stehouwer CDA, Netelenbos JC, Kenemans P.
Gynecol Endocrinol 1999;13:130-144.13. Postmenopausal oestradiol-dydrogesterone therapy favourably affects fibrinolysis and Lp(a) in healthy women.
Mijatovic V, Kenemans P, Mooren MJ van der, Emeis JJ, Baal WM van, Peters-Muller ER, Stehouwer CDA..
Fibrinolysis & Proteolysis 1999;13:177-183.14. Homocysteine and fibrinolysis in acute occlusive coronary events (comment).
Mooren MJ van der, Kenemans P.
Lancet 1999;354:1475.15. Menopause research in the new millennium - the European HRT Network Foundation: its raison d'être.
Mooren MJ van der, Kenemans P.
Medicographia 1999;21:245-248.16. Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer.
Scheele F, Burger CW, Kenemans P.
Maturitas 1999;33:191-196.17. Towards a healthier postmenopause; effects of oestrogen and raloxifene on markers of bone and cardiovascular health.
Valk- de Roo GW de.
Dissertation, 1999, Vrije Universiteit Amsterdam18. Homocysteine is associated with plasma endothelin and von Willebrand Factor, but not with endothelium-dependent vasodilatation in healthy postmenopausal women.
Valk - de Roo GW de, Stehouwer CDA, Lambert J, Schalkwijk CG, Mooren MJ van der, Netelenbos JC.
Clin Chem 1999;45:1200-1205.19. What's the bleeding point.
Weijer PHM van de.
Dissertation, 1999, Vrije Universiteit Amsterdam20. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy.
Weijer PHM van de, Barentsen R, Vries MH de, Kenemans P.
Obstet Gynecol 1999;93:551-55721. Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone.
Weijer PHM van de, Mooren MJ van der, Barentsen R, Kenemans P.
Climacteric 1999;2:101-109.
1998
1. Progestogens in HRT: are the differences clinically relevant?
Barentsen R, Weijer PHM van de, Kenemans P.
Menopause Review 1998;3:7-12.2. Postmenopausal hormone replacement therapy and cancer of the female genital tract and breast.
Burger CW, Kenemans P.
Curr Opinion Obstet Gynecol 1998;10:41-45.3. Ambulatory - not office - blood pressures decline during hormone replacement therapy in postmenopausal women.
Ittersum FJ van, Baal WM van, Kenemans P, Mijatovic V, Donkers AJM, Mooren MJ van der, Stehouwer CDA.
Am J Hypertension 1998;11:1147-1152.4. A randomized controlled study of the effects of 17ß-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women.
Mijatovic V, Kenemans P, Jacobs C, Baal WM van, Peters-Muller ERA, Mooren MJ van der.
Obstet Gynecol 1998;91:432-436.5. Postmenopausal oral 17ß-oestradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
Mijatovic V, Kenemans P, Netelenbos JC, Jacobs C, Popp-Snijders C, Peters-Muller ERA, Mooren MJ van der.
Fertil Steril 1998;69:876-882.6. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine in healthy postmenopausal women.
Mijatovic V, Netelenbos JC, Mooren MJ van der, Valk-de Roo GW de, Jakobs C, Kenemans P.
Fertil Steril 1998;70:1085-1089.7. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease.
Mooren MJ van der, Mijatovic V, Baal WM van, Stehouwer CDA.
Maturitas 1998;30:27-36.8. Hormone replacement therapy and cardioprotection in the elderly.
Pines A, Kessel H, Mijatovic V, Mooren MJ van der.
J R Soc Med 1998;91:1-4.9. Hormone replacement therapy and the vaginal bleeding issue.
Weijer PHM van de, Barentsen R, Kenemans P.
Gynecol Endocrinol 1998;30:257-263.10. Estrogen replacement and vaginal bleeds.
Weijer PHM van de, Barentsen R.
Menopause Review 1998;3:13-16.
1997
1. Postmenopausal hormone replacement therapy and cancer of the female genitalil tract and the breast.
Burger CW, Koomen I, Peters NAJB, Leeuwen FE van, Kenemans P.
Eur Menopause J 1997;4:23-26.2. Hormone replacement and the menopause: a European position paper.
Crosignani PG, Kenemans P, Paoletti R, Soma MR, Woodford FP.
Eur J Obstet Gynecol Reprod Biol 1997;74:67-72.3. Hormone replacement therapy and breast cancer morbidity, mortality and recurrence.
Kenemans P, Scheele F, Burger CW.
Eur J Obstet Gynecol Reprod Biol 1997;71:199-203.4. Oral 17ß-Oestradiol continuous combined with dydrogesterone lowers serum lipoprotein(a) in healthy postmenopausal women.
Mijatovic V, Kenemans P, Netelenbos JC, Peters-Muller ERA, Kamp GJ van, Voetberg GA, Weijer PHM van de, Mooren MJ van der.
J Clin Endocrinol Metab 1997;82:3543-3547.5. Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations.
Pines A, Mijatovic V, Mooren MJ van der, Kenemans P.
Eur J Obstet Gynecol Reprod Biol 1997;71:193-197.6. HRT in patients at high risk of primary or recurrent breast cancer.
Scheele F, Kenemans P.
Menopause Review 1997;2:48-55.7. Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover.
Valk-de Roo GW de, Netelenbos JC, Peters-Muller ERA, Voetberg GA, Weijer PHM van de, Bouman AA, Popp-Snijders C, Kenemans P.
Maturitas 1997;28:153-162.
